GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arix Bioscience PLC (LSE:ARIX) » Definitions » Insider Ownership

Arix Bioscience (LSE:ARIX) Insider Ownership : 7.85 % (As of May. 25, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Arix Bioscience Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arix Bioscience's insider ownership is 7.85%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arix Bioscience's Institutional Ownership is 2.69%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arix Bioscience's Float Percentage Of Total Shares Outstanding is 0.00%.


Arix Bioscience Insider Ownership Historical Data

The historical data trend for Arix Bioscience's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arix Bioscience Insider Ownership Chart

Arix Bioscience Historical Data

The historical data trend for Arix Bioscience can be seen below:

2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31
Insider Ownership 7.50 7.75 7.75 7.75 7.75 7.75 7.80 7.85 7.85 7.85

Arix Bioscience Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Arix Bioscience (LSE:ARIX) Business Description

Traded in Other Exchanges
N/A
Address
50 Duke Street, Duke Street House, London, GBR, W1K 6JL
Arix Bioscience PLC is a healthcare and life science company. Its business model is to source, finance, and develop healthcare and life science businesses that deliver or seek to deliver therapies to patients. Its segment includes sourcing, financing, and developing healthcare and life science businesses globally.

Arix Bioscience (LSE:ARIX) Headlines

No Headlines